echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JAMA Netw Open: The effects of the new weight loss drug Bimagrumab on the quality of body fat in type 2 diabetes and obesity

    JAMA Netw Open: The effects of the new weight loss drug Bimagrumab on the quality of body fat in type 2 diabetes and obesity

    • Last Update: 2021-01-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In primary care facilities, more than half of patients are overweight and obese, often accompanied by insulin resistance, chronic inflammation and associated co-diseases.
    obesity can be successfully controlled through lifestyle programs, long-term success rates for weight loss outside professional centers remain limited.
    , only a small percentage of severely obese patients can undergo bariatric surgery.
    combination of lifestyle management and medication is an effective and safe treatment option for more and more obese patients.
    five drugs have been approved for long-term use by the U.S. Food and Drug Administration (FDA), while one has recently been withdrawn and some new weight-loss drugs are under development.
    a new drug for obesity and associated metabolic disorders is bimagrumab (BYM338), an all-human monoclonal antibody that binds to the active type II receptor (ActRII) and blocks the effects of natural ligands, thereby negatively regulating the growth of skeletal muscles.
    in preclinical animal models, ActRII blocking also promotes roles other than skeletal muscle, including effects on brown adipose tissue (BAT) differentiation and activity.
    During the 10-week study, a single intravenous bimagrumab not only increased non-lipid quality in human participants, but also significantly reduced total fat mass (FM) and improved insulin sensitivity in healthy insulin resistance volunteers who did not diet.
    these observations suggest that bimagrumab may represent a new approach to treating patients with obesity and associated metabolic disorders.
    , a new study published recently on JAMA Network Open identifies the effectiveness and safety of bimagrumab in body composition and blood sugar control in adults who are overweight or obese and type 2 diabetes.
    The double-blind, placebo-controlled, 48-week, Phase 2 randomized clinical trial was conducted in adults with type 2 diabetes in nine regions of the United States and the United Kingdom, with a body mass index of between 28 and 40 and levels of hemoglobin glycation (HbA1c) between 6.5 and 10.0 percent.
    trials were conducted from February 2017 to May 2019.
    only participants who completed a complete treatment plan were included in the analysis.
    patients were randomly treated with intravenous bimagrumab (10 mg/kg, 5% glucose solution up to 1200 mg) or placebo (5% glucose solution) every 4 weeks for 48 weeks; Both groups received dietary and exercise counseling.
    The primary endpoint is the smallest 2000 mean change from baseline check to week 48 body fat mass (FM), and secondary and exploratory endpoint is change from baseline check to week 48 thin weight (LM), waist circumference (WC), HbA1c level, and weight (BW).
    a total of 75 patients were randomized into the bimagrumab group (n=37; 23 (62.2%) women) or the placebo group (n=38; 12 (31.6%) women) and 58 (77.3%) completed 48 weeks of the study.
    (standard deviation) age of patients at the time of baseline examination was 60.4 (7.7) years, the average (standard deviation) BMI was 32.9 (3.4), and the average (standard deviation) weight was 93.4 6 (14.9) kg; average (standard deviation) FM 35.4 (7.5) kg; average (standard deviation) HbA1c level 7.8% (1.0%).
    48 weeks, the changes in bimagrumab vs placebo were as follows: FM, 20.5% vs 0.5%; LM, 3.6% vs. 0.8%; WC, 9.0 cm vs 0.5 cm; HbA1c level, 0.76% vs 0.04%; and weight 6.5% vs 0.8%.
    security and tolerance of Bimagrumab is consistent with previous studies.
    the non-lipid weight increase observed in participants treated with bimagrumab may have been due to the accumulation of fluid or water rather than an increase in muscle protein.
    did not measure body water content or muscle moisture content, the researchers were not aware of any effect of bimagrumab on water balance in this study or in earlier related studies.
    , the researchers believe that non-lipid weight estimates represent normal hydration of skeletal muscles, a hypothesis that could be tested in a further phase II study in the future.
    , the cause of the change in energy balance behind weight loss is still unknown.
    in this Phase 2 randomized clinical trial, bimagrumab combined actRII blocking the treatment to significantly reduce FM, LM increase, and metabolism improvement in patients with type 2 diabetes who were overweight or obese.
    ActRII path pathpy inhibition may provide a new approach to drug management of obesity and associated metabolic disorders.
    : Heymsfield SB, Coleman LA, Miller R, et al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2021; 4(1):e2033457. doi:10.1001/jamanetworkopen.2020.33457MedSci Original Source: MedSci Original Copyright Notice: All noted on this website "Source: Mets Medicine" or "Source: MedSci Original" text, images and audio and video materials, copyrights are owned by Metz Medical, without authorization, no media, website or individual may reproduce, authorized to reproduce with the words "Source: Mets Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    at the same time reproduced content does not represent the position of this site.
    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.